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Potential role of costimulatory pathways in
immune dysfunction in hemodialysis
patients
To the Editor:
We read with interest the paper by Mathew et al. who
investigated the role of T-regulatory cells in the immune
response to HBV vaccination in patients undergoing hemo-
dialysis (HD).1
This is a very important topic, since response to vac-
cines is commonly considered an expression of immune
status in HD. The authors, in agreement with previous
reports, demonstrated that in HD there is a low rate of
response to vaccine, but they did not find any significant
difference in T-regulatory cell number between healthy
controls and HD subjects.
We think that this negative result could depend by the
fact that immune dysfunction in HD patients involves
alterations of various types of immune cells, including
polymorphonuclear leukocytes, monocytes, natural killer
cells, B and T lymphocytes2,3 and probably the simple
study of the number of T-regulatory cells and their sub-
types is not sufficient to describe this condition.
Indeed, in this complex picture T cell dysfunction can
occur at different levels.
In this regards, in the last years, many studies have dem-
onstrated that co-stimulatory signal alterations may play a
role in determining immunodeficiency in HD.4
Costimulatory pathways (CD28, TNF-related, adhesion,
and TIM molecules) regulate the interactions between
receptors on the T cells and their ligands expressed on sev-
eral cell types and are essential for the full activation of
na€ıve T cells after antigen-specific recognition.5
Girndt et al. found a correlation among the low expres-
sion of CD80 and CD86 (CD28 ligands) on monocytes iso-
lated from HD patients, impaired proliferation ability of T
cells and reduced response to HBV vaccination.6
Similar results were also found analyzing the TNF-
related CD40/CD40L pathway, which in HD patients
presents a whole imbalance characterized by reduction of
CD40 membrane expression associated with elevated levels
of the soluble form of CD40 (sCD40).7 Interestingly, Con-
tin et al. showed that HD patients with higher serum levels
of sCD40, which may act as a natural antagonist of
CD40/CD40L interaction, were less responsive to HBV
vaccine, whereas sCD40 removal, obtained by the use of
polymethylmethacrylate-based dialysis membranes, was
associated with a significant improvement of response to
vaccination.8
All together these evidence suggest that the study
of HD-related immunodeficiency should take into
consideration the complexity of the different path-
ways involved and their interaction, also because the
comprehension of cellular and humoral mechanisms
underlying immune dysfunction could provide new
therapeutic targets.
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